[mRNA quantification. The next challenge in routine diagnostics].
The application of predictive biomarkers results in an increase in the response rates and overall survival of cancer patients. This had been shown impressively for the detection of mutations in the proto-oncogenes KRAS and EGFR for the application of anti-EGFR targeted therapies in metastatic colorectal carcinomas and non-small-cell lung cancer, respectively. This mutation detection is of a qualitative nature. In addition, predictive biomarkers are known for the use of the commonly administered chemotherapeutics 5-fluorouracil, platinum-containing complexes, and Irinotecan, which are normally identical to the targets of the therapeutic compounds. The determination of these predictive biomarkers also results in an increase in response rates and overall survival. However, this detection is done via the quantitative determination of mRNA expression levels, implying greater efforts in detection, knowledge of cut-off levels, and higher requirements for nationwide establishment.
Jung
A
A
Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337 München. andreas.jung@lmu.de
Jaitner
S
S
Schäffauer
A J
AJ
Kirchner
T
T
D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016503:Drug Delivery Systems; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D025202:Molecular Diagnostic Techniques; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011237:Predictive Value of Tests; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics*; D015996:Survival Rate; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D000077150:Oxaliplatin; D000077146:Irinotecan; D013940:Thymidylate Synthase; D005472:Fluorouracil; D002166:Camptothecin
Int J Cancer. 2006 Nov 15;119(10):2435-42
16894565
J Clin Oncol. 2001 Dec 1;19(23):4298-304
11731512
Z Gastroenterol. 2008 Aug;46(8):799-840
18759205
Biotechniques. 2004 Jun;36(6):1030-7
15211754
Am J Pharmacogenomics. 2003;3(2):73-88
12749725
Clin Cancer Res. 2000 Apr;6(4):1322-7
10778957
Nat Rev Cancer. 2009 Jul;9(7):489-99
19536109
Science. 2008 Sep 26;321(5897):1801-6
18772397
J Clin Oncol. 1997 Oct;15(10):3223-9
9336359
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
11240971
Pathologe. 2010 Feb;31(1):16-21
19957085
Clin Cancer Res. 1998 Oct;4(10):2371-6
9796967
Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205
12084461
Am J Surg. 1968 Feb;115(2):140-7
5635578
Cell. 2000 Jan 7;100(1):57-70
10647931
Nature. 2001 May 17;411(6835):366-74
11357144
Scand J Clin Lab Invest Suppl. 2010;242:63-5
20515280
J Clin Oncol. 2008 Sep 1;26(25):4131-7
18757326